Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Green Tea Extract Shows Promise In Leukemia Trials
Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea. The trial determined that patients with chronic lymphocytic leukemia (CLL) can tolerate the chemical fairly well when high doses are administered in capsule form and that lymphocyte count was reduced in one-third of participants. The findings appear today online in the Journal of Clinical Oncology.
generic viagra online
A Simpler Definition For Major Depressive Disorder
Researchers from Rhode Island Hospital"s department of psychiatry propose that the definition for major depressive disorder (MDD) should be shortened to include only the mood and cognitive symptoms that have been part of the definition in the Diagnostic and Statistical Manual of Mental Disorders (DSM) for the past 35 years. Their recommendation would exclude those symptoms that are currently part of the definition that may be associated with medical illness rather than depression. The proposal is based on a study that appears in the July 23 online first edition of the journal Psychological Medicine.
News of the day
New Insights Into The Mystery Of "High Risk Platelets" From Diabetic Donors
Amid emerging concerns that blood platelets donated for transfusion by individuals with Type 2 diabetes may be unsafe, scientists are reporting the first detailed identification and analysis of a group of abnormal proteins in platelets from diabetic donors. The study could lead to screening tests to detect and monitor these so-called "high risk platelets," the researchers say. Their study is scheduled for the June 5 issue of ACS" Journal of Proteome Research, a monthly publication. About 18 million people in the United States have Type 2 diabetes, and the disease is spreading with the epidemic of obesity.
Oncology

Philips Expands Home Healthcare Commitment With Portable Life-support Ventilator

Royal Philips Electronics (NYSE: PHG, AEX: PHI) introduced the Trilogy100 portable at-home life-support ventilator. The highly versatile, lightweight (11 lb / 5 kg) device marks a milestone in home ventilation from a recognized leader in respiratory care. Respironics first introduced bi-level positive airway pressure for noninvasive ventilation nearly 20 years ago. Today, Philips Respironics offers a broad range of clinically proven solutions intended to support breathing in the intensive care, sub-acute, and home care settings. Developed to meet the needs of a wide range of patients, Trilogy100 offers both volume- and pressure-control ventilation for adult and pediatric use with features intended to help caregivers and clinicians administer patient care in the home and alternative care settings such as skilled nursing facilities. A growth area, the number of home ventilator-dependent patients has risen in the 1980s and 1990s -- a result of increased survival rates of critically ill patients and technological advances, such as noninvasive ventilation, which can prolong and improve quality of life.1 "When developing the Trilogy100 ventilator, we focused on areas for clinicians and caregivers that are most important in delivering home respiratory care - ease of use, versatility and portability," explains John Frank, vice president and general manager, Home Respiratory Care, Philips Home Healthcare Solutions. "The integration of the three makes Trilogy100 a significant advancement in home respiratory care." Trilogy100 features Respironics" proven bi-level technology with advanced leak compensation, enabling the patient to receive more types of therapy from a single device. The system streamlines the ventilation process with interchangeable active and passive exhalation ports and the flexibility to choose the best available circuit and patient interface. Trilogy100 can accommodate a mask, mouthpiece or tracheostomy. The portable ventilator also can eliminate cumbersome valves and tubing by utilizing the passive circuit with Whisper Swivel II for invasive ventilation. For patient mobility, the compact design includes detachable, internal, and external power options, with up to 6 hours of battery capacity. Patients can be as active as possible while using the ventilator to support their breathing. The Trilogy100 ventilator"s intuitive design allows for quick access to device settings and patient information. The easy-to-read, easy-to-navigate screens and clear, concise directions offer simplified patient views. In addition, optional DirectView patient data management software allows clinicians to more efficiently manage ventilation therapy with access to full patient information, including waveforms, trends, usage patterns, and summary statistics. The Trilogy100 life-support ventilator is backed by Philips Respironics service and support programs, including a 24/7 call center staffed with clinical and technical specialists, in-depth ventilation workshops, and educational training res. 1Simonds, A.K. "Home ventilation." European Respiratory Journal 2003; 22: Suppl. 47, 38s-46s. Royal Philips Electronics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009